Toledano Miranda Jayne 4

What Happened

• Jayne Toledano, CEO of Entera Bio Ltd. (ENTX), was awarded a total of 420,560 stock-settled restricted stock units (RSUs) on July 14, 2026. The grant consists of 347,567 RSUs (in lieu of her 2025 annual cash bonus) and 72,993 RSUs (in lieu of $100,000 of 2026 base salary). Each award is shown at $0.00 per share in the filing because these are compensation awards, not open-market purchases.

Key Details

• Transaction date: July 14, 2026; Form 4 filed July 16, 2026 (appears timely).
• Shares/units awarded: 347,567 RSUs (F1) + 72,993 RSUs (F2) = 420,560 RSUs total; acquisition price reported $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Material footnotes: Grants were approved by the Board on May 7, 2026 and approved by shareholders on July 14, 2026. RSUs vest ratably quarterly over a one-year period beginning May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
• Transaction type: Award/Grant (code "A"); these RSUs convert to ordinary shares as they vest (not an immediate sale).

Context

• These awards are compensation-related (awarded in lieu of cash) and are not the same signal as an insider buying shares; they increase the CEO’s potential future ownership as the RSUs vest. Because vesting is spread over one year (and can accelerate on a Change in Control), the economic impact to the CEO is realized over time rather than immediately.